The 340B Drug Pricing Program was created in 1992 with a clear purpose. Congress intended it to help safety-net providers serve low-income patients by allowing them to purchase prescription drugs at steep discounts. For years, it appeared to work as designed.
Today, it has become something very different.
According to reporting by The Epoch Times and multiple policy analyses, the program has grown into a massive, poorly controlled revenue engine dominated by large hospital systems. What was once a targeted effort to help the poor now increasingly benefits some of the most powerful players in American health care.
How the Program Works
The mechanics of 340B are simple but powerful. Pharmaceutical manufacturers are required to sell outpatient drugs at discounted prices to qualifying providers, known as covered entities. These include community health centers, rural hospitals, and clinics serving vulnerable populations.
Those providers then dispense the drugs to patients and bill insurers or patients at full retail price. The difference between the discounted purchase price and the reimbursement becomes revenue.
Here is the critical issue. Hospitals are not required to pass those savings to patients. They are not even required to report how the money is used.
That lack of accountability has shaped everything that followed.
The Affordable Care Act Changed Everything
The turning point came with the Affordable Care Act.
The law expanded Medicaid, allowing many more hospitals to qualify for the program. At the same time, federal regulators allowed hospitals to contract with an unlimited number of retail pharmacies instead of just one.
That change unleashed explosive growth.
Participation expanded from fewer than 10,000 entities to more than 53,000 sites. Hospitals now dominate the program, accounting for roughly 80 percent of all 340B drug purchases.
What had been a narrow safety-net program became a nationwide financial pipeline.
A System Built for Consolidation
The structure of 340B created a powerful incentive for expansion. Once a hospital qualifies, every affiliated clinic, physician, and outpatient site also qualifies.
That means every prescription written inside a hospital system can generate profit.
Hospitals responded exactly as expected. They acquired physician practices, expanded into wealthier communities, and built large integrated systems.
In 2012, only 26 percent of physicians worked for hospitals. By 2024, more than half did.
Independent practices have been pushed aside, not because they cannot treat patients, but because they cannot access the same pricing advantages.
The Scale of the Money
The numbers reveal just how far the program has drifted.
In 2024, covered entities spent more than $81 billion on discounted drugs. Disproportionate share hospitals alone accounted for $64 billion of that total.
Research published in the New England Journal of Medicine found that hospitals often marked up drugs between two and six times their purchase price, with median margins exceeding 300 percent.
The University of California health system reported generating at least $1.3 billion in 340B savings in a single year.
This is not marginal support for struggling clinics. It is a massive revenue stream.
A Black Box With No Transparency
The program operates with striking secrecy.
Drug prices under 340B are confidential. Hospitals do not have to disclose how much they earn or how they spend it.
Even supporters of the program acknowledge the problem. Tammy Baldwin said transparency is essential so “we know where the money is going.”
Bill Cassidy has been even more direct, warning that the program’s growth has occurred with “limited oversight” and raising questions about whether it actually benefits low-income patients.
Right now, there is no clear answer.
The most revealing statistic is this. Between 2013 and 2021, the number of low-income patients targeted by the program dropped by half, yet revenue nearly quadrupled.
At the same time, many contract pharmacies are located in wealthier areas, not underserved communities.
Rural health care continues to decline. Rural physicians are disappearing, and dozens of rural hospitals have closed.
If the program were functioning as intended, these trends would not exist.
Courts Are Beginning to Push Back
The legal system has started to recognize the gaps in the program.
Drug manufacturers have challenged the use of unlimited contract pharmacies, and federal appellate courts have largely sided with them. Courts have ruled that the statute does not clearly require manufacturers to support unlimited distribution arrangements.
They have also limited the authority of the Health Resources and Services Administration, making clear that the agency cannot stretch vague statutory language to justify broad control.
The message from the courts is clear. The law is ambiguous, and the current system has moved beyond what Congress explicitly authorized.
Mitch Roob and the Push for Reform
One of the most direct critics of the current system is Mitch Roob. Mitch Roob is the Secretary of the Indiana Family and Social Services Administration, overseeing the state’s Medicaid program and health policy initiatives. He has become a leading voice pushing to reform the 340B program, arguing it has been misused to boost hospital profits instead of directly benefiting low-income patients.
Roob argues that the program is being used to subsidize hospital profits without benefiting patients. His position is blunt. “No federal law guarantees hospitals the right to retain revenue derived from prescriptions funded by a taxpayer-supported program.”
He has proposed reforms that would redirect savings back into Medicaid, ensuring that funds actually benefit patients rather than hospital balance sheets. Indiana estimates those changes could save about $60 million per year.
His goal is to restore the program to its original purpose.
The Defense From Hospitals
Hospitals and advocates argue that the program remains essential.
Systems like Henry Ford Health say 340B revenue supports large amounts of uncompensated care. The Cleveland Clinic Foundation argues that participation helps ensure access to care for all patients.
Some advocates also claim pharmaceutical companies are trying to weaken the program to protect their own profits.
There is some truth in these arguments. Certain safety-net providers do rely on 340B funds.
But that does not explain the scale of growth, the concentration of benefits among large systems, or the lack of transparency.
A Program That Has Lost Its Way
Even reform advocates now acknowledge that the program has become “an inefficient, poorly targeted revenue stream for large hospital systems.”
It incentivizes consolidation, rewards higher drug prices, and operates with minimal oversight.
The original goal was to help low-income patients. Today, the incentives reward size, expansion, and revenue generation.
What began as a focused effort to support vulnerable patients has become a sprawling system that benefits large hospital networks, distorts markets, and operates with limited accountability.
Lawmakers like Bill Cassidy and Tammy Baldwin have called for reform. Officials like Mitch Roob are pushing for structural change.
The core issue is no longer debated. The program is not working as intended.
Without meaningful reform, it will continue to grow, continue to consolidate power in large health systems, and continue to move further away from the patients it was meant to serve.
